Polarean Imaging PLC PLLWF

Company Overview

Polarean Imaging plc is a medical imaging technology company focused on advanced pulmonary imaging using hyperpolarized xenon-129 (Xe-129) magnetic resonance imaging (MRI). The company operates within the medical imaging, pulmonary diagnostics, and healthcare technology sectors, with a primary emphasis on improving visualization and assessment of lung function. Its core commercial platform is the Xenoview imaging agent and associated MRI imaging workflow, which enables clinicians to evaluate regional lung ventilation and gas exchange in ways that conventional imaging modalities may not provide. The company primarily serves hospitals, academic medical centers, pulmonary specialists, and research institutions involved in respiratory disease diagnosis and monitoring.

The company traces its origins to technology developed at academic institutions focused on hyperpolarized gas MRI research and was incorporated in the United Kingdom while maintaining significant operational activities in the United States. Polarean evolved from a research-oriented imaging technology developer into a commercial-stage healthcare company following U.S. regulatory clearance for its Xenoview platform. Its strategic positioning is based on proprietary hyperpolarization technology, specialized imaging expertise, and early-mover status in functional pulmonary MRI, particularly in diseases such as chronic obstructive pulmonary disease (COPD), asthma, interstitial lung disease, and cystic fibrosis.